HealthcareLarge capRs 97,353 crRs 286.4 cr traded a dayManufacturingHealthcarePharmaceuticals
Close on 2026-08-21
1,802.00
−1.26%
52-week range95% of the way up
832.301,858.00
Market cap
97,353 cr
P/E (TTM)
89.3×
industry 44×
EPS (TTM)
20.19
Revenue YoY
+29.1%
Q1 FY27
Profit YoY
+123.9%
Net margin
17.9%
+7.6pt vs a year ago
Growth trend
+23.8pt
vs last quarter’s YoY
1 month
+14.9%
Below 52w high
3.1%
RSI (14)
48
Daily swing
2.0%
average true range
Volume
0.6×
vs 20-day average
Traded
Rs 286 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+0.82%
1 month
+14.90%
3 months
+31.16%
6 months
+64.91%
1 year
+109.51%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 2 against, 0 worth knowing
Supporting
trading 47% above its 200-day average
sitting at 95% of its 52-week range, with little overhead supply from trapped buyers
up 110% over twelve months
matches the market's strongest stocks, which has beaten the market by +0.37 points over 20 sessions across 48,607 past signals
4 independent kinds of evidence agree today, which is uncommon
revenue grew 29% year on year in the quarter ending 2026-06-30
net margin has widened from 11.8% to 17.9% across four quarters
futures show a long buildup — the move is being funded by new positions
Against
2 of the scans it matches have historically underperformed the market
priced at 89× earnings against an industry median of 44× — 103% above its peers
Worth knowing
nothing the data supports either way
LAURUSLABS sits in Manufacturing, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 1,230, its 200-day average; a failure to hold the top of its 52-week range; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
How it has performed
price return over each window, measured against zero
What the scans say today
11 of 47 matched on 2026-08-21
LAURUSLABS matches 11 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
LAURUSLABS trades at 89× trailing earnings, close to its median of 94× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 29% against the same quarter a year earlier
profit rose 124% year on year
net margin widened from 15.6% to 17.9%
revenue rose in 4 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
2,026
481
362
6.81
17.9%
Q4 FY26
2026-03-31 · consolidated
1,812
361
282
5.17
15.6%
Q3 FY26
2025-12-31 · consolidated
1,778
327
252
4.67
14.2%
Q2 FY26
2025-09-30 · consolidated
1,653
270
194
3.61
11.8%
Q1 FY26
2025-06-30 · consolidated
1,570
224
162
3.02
10.3%
Q4 FY25
2025-03-31 · consolidated
1,720
312
233
4.34
13.5%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+10.9%
Versus 200-day average+46.6%
Below 52-week high-3.0%
Above 52-week low+116.5%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)48.1
Higher closes in last 53 of 5
Six-month return+64.91%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)1.97%
Volume versus 20-day0.6x
Median daily turnoverRs 286.4 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Long Buildup
Price up, open interest up. New buyers are arriving rather than old sellers leaving — the move is being funded, not squeezed.
Futures basis versus spot-0.32%
Open interest change+2.5%
Put / call ratio0.78
Put wall (support)1,700
Call wall (resistance)1,860
Max pain1,740
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 67 classified companies
LAURUSLABS trades at 89.3× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 103%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-19
4
The market's strongest stocks, Beating the market for 6 months, Bearish engulfing, Above the 200-day EMA